Health Catalyst (HCAT) Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Health Catalyst in the last twelve months. There are currently 4 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HCAT shares.
View HCAT analyst ratings or view top-rated stocks.

10 brokerages have issued 12 month target prices for Health Catalyst's stock. Their HCAT share price forecasts range from $8.00 to $18.00. On average, they predict the company's share price to reach $14.55 in the next twelve months. This suggests a possible upside of 37.1% from the stock's current price.
View analysts price targets for HCAT or view top-rated stocks among Wall Street analysts.

Health Catalyst's stock was trading at $10.63 at the beginning of the year. Since then, HCAT stock has decreased by 0.2% and is now trading at $10.61.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our HCAT earnings forecast.

Health Catalyst, Inc. (NASDAQ:HCAT) issued its earnings results on Tuesday, August, 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.09. The company had revenue of $73.21 million for the quarter, compared to the consensus estimate of $72.67 million. Health Catalyst had a negative net margin of 51.76% and a negative trailing twelve-month return on equity of 16.49%.

ETFs with the largest weight of Health Catalyst (NASDAQ:HCAT) stock in their portfolio include Fidelity Digital Health ETF (FDHT), ROBO Global Healthcare Technology and Innovation ETF (HTEC), SPDR FactSet Innovative Technology ETF (XITK) and First Trust Nasdaq Lux Digital Health Solutions ETF (EKG).iShares U.S. Healthcare Providers ETF (IHF).

Health Catalyst issued an update on its third quarter 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $70.20 million-$74.20 million, compared to the consensus revenue estimate of $72.86 million.

501 employees have rated Health Catalyst Chief Executive Officer Dan Burton on Glassdoor.com. Dan Burton has an approval rating of 99% among the company's employees. This puts Dan Burton in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 83.0% of employees surveyed would recommend working at Health Catalyst to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Health Catalyst investors own include NVIDIA (NVDA), Salesforce (CRM), Alteryx (AYX), Walt Disney (DIS), DocuSign (DOCU), Block (SQ), Slack Technologies (WORK), ServiceNow (NOW), Marvell Technology (MRVL) and PayPal (PYPL).

(HCAT) raised $129 million in an initial public offering on Thursday, July 25th 2019. The company issued 6,000,000 shares at $20.00-$23.00 per share. Goldman Sachs, J.P. Morgan and William Blair served as the underwriters for the IPO and Piper Jaffray, Evercore ISI, SVB Leerink and SunTrust Robinson Humphrey were co-managers.

Health Catalyst trades on the NASDAQ under the ticker symbol "HCAT."

Health Catalyst's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.46%), Point72 Asset Management L.P. (4.21%), State Street Corp (2.49%), Goldman Sachs Group Inc. (2.20%), Dimensional Fund Advisors LP (2.14%) and Granahan Investment Management LLC (2.04%). Insiders that own company stock include Anita Pramoda, Benjamin Landry, Bryan Richard Hinton, Bryan Truman Hunt, D Fraser Bullock, Daniel D Burton, Daniel H Orenstein, Duncan Gallagher, James Patrick Jr Nelli, Jason Alger, Linda Llewelyn, Paul Horstmeier and Timothy G Ferris.
View institutional ownership trends.

Shares of HCAT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HCAT stock can currently be purchased for approximately $10.61.

Health Catalyst (NASDAQ:HCAT) has a market capitalization of $604.35 million and generates $276.24 million in revenue each year. The company earns $-137,400,000.00 in net income (profit) each year or ($2.68) on an earnings per share basis.

The company employs 1,200 workers across the globe.

Health Catalyst's mailing address is 3165 MILLROCK DRIVE SUITE 400, SALT LAKE CITY UT, 84121. The official website for the company is www.healthcatalyst.com. The company can be reached via phone at (801) 708-6800 or via email at ir@healthcatalyst.com.